Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 4, 2014, Pages 480-489

  Mahmud, Nadim ^a   Petro, Benjamin ^a   Baluchamy, Sudhakar ^a   Li, Xinmin ^b   Taioli, Simona ^a   Lavelle, Donald ^a   Quigley, John G ^a   Suphangul, Montha ^a   Araki, Hiroto ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epigenetic modification; Exvivo expansion; Hematopoiesis; Stem and progenitor cells; Transplantation: basic biology; Umbilical cord blood

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD34 ANTIGEN; CELL DNA; THY 1 ANTIGEN; TRICHOSTATIN A; VALPROIC ACID;

ARTICLE; CELL LEVEL; CELL LOSS; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; STEM CELL EXPANSION; TRANSPLANTATION; UMBILICAL CORD BLOOD; XENOTRANSPLANTATION;

EPIGENETIC MODIFICATION; EX VIVO EXPANSION; HEMATOPOIESIS; STEM AND PROGENITOR CELLS; TRANSPLANTATION: BASIC BIOLOGY; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; ANTIGENS, THY-1; AZACITIDINE; CELL PROLIFERATION; CELLS, CULTURED; DNA METHYLATION; EPIGENESIS, GENETIC; FETAL BLOOD; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, INBRED NOD; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS; VALPROIC ACID;

EID: 84895804153     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.12.562     Document Type: Article

References (40)

1. Koury M., Mahmud N., Rhodes M. Origin and development of blood cells. Wintrobe's clinical hematology 2009, 79-105. Lippincott Williams & Wilkins, Philadelphia, PA. J.P. Greer, J. Foerster, G.M. Rodgers (Eds.).
2. Zon L.I. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 2008, 453:306-313.
3. Araki H., Baluchamy S., Yoshinaga K., et al. Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues. Exp Hematol 2009, 37:1084-1095.
4. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. NEngl J Med 2001, 344:1815-1822.
5. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009, 147:262-274.
6. Boitano A.E., Wang J., Romeo R., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329:1345-1348.
7. Delaney C., Heimfeld S., Brashem-Stein C., et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
8. Goessling W., Allen R.S., Guan X., et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011, 8:445-458.
9. Himburg H.A., Muramoto G.G., Daher P., et al. Pleiotrophin regulates the expansion and regeneration of hematopoietic stem cells. Nat Med 2010, 16:475-482.
10. de Lima M., McNiece I., Robinson S.N., et al. Cord-blood engraftment with exvivo mesenchymal-cell coculture. NEngl J Med 2012, 367:2305-2315.
11. Fiskus W., Wang Y., Sreekumar A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
12. Jabbour E., Issa J.P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008, 112:2341-2351.
13. Kuendgen A., Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007, 110:943-954.
14. Shi J., Zhao Y., Ishii T., et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 2007, 67:6417-6424.
15. Wang X., Zhang W., Tripodi J., et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 2010, 116:5972-5982.
16. Araki H., Mahmud N., Milhem M., et al. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol 2006, 34:140-149.
17. Mahmud N., Milhem M., Araki H., Hoffman R. Alteration of Hematopoietic Stem Cell Fates by Chromatin-Modifying Agents. Stem Cell Transplantation 2006, 27-42. Weinheim Wiley-VCH Verlag GmbH & Co. KGaA, Germany. A.D. Ho, R. Hoffman, E.D. Zanjani (Eds.).
18. Araki H., Yoshinaga K., Boccuni P., et al. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood 2007, 109:3570-3578.
19. Milhem M., Mahmud N., Lavelle D., et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004, 103:4102-4110.
20. Araki H., Baluchamy S., Petro B., et al. Valproic acid results in maintenance but not expansion of transplantable hematopoietic stem cells from human umbilical cord blood. Blood 2010, 116:827A.
21. Bug G., Gül H., Schwarz K., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65:2537-2541.
22. De Felice L., Tatarelli C., Mascolo M.G., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005, 65:1505-1513.
23. Seet L.F., Teng E., Lai Y.S., et al. Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur J Haematol 2009, 82:124-132.
24. Conneally E., Cashman J., Petzer A., Eaves C. Expansion invitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci USA 1997, 94:9836-9841.
25. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. JImmunol 1981, 126:1614-1619.
26. Sankar N., Baluchamy S., Kadeppagari R.K., et al. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008, 27:5717-5728.
27. Reeves M.E., Baldwin S.W., Baldwin M.L., et al. Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer 2010, 10:562.
28. Warren L., Manos P.D., Ahfeldt T., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
29. Yang A.S., Estecio M.R., Doshi K., et al. Asimple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32:e38.
30. Baluchamy S.P., Araki H., Lindgren V., Mahmud N. Possible epigenetic regulation of functionally opposing groups of genes involved in exvivo expansion of cord blood stem cells. Blood 2008, 112:3473A.
31. Oswald J., Steudel C., Salchert K., et al. Gene-expression profiling of CD34+ hematopoietic cells expanded in a collagen I matrix. Stem Cells 2006, 24:494-500.
32. Pang W.W., Price E.A., Sahoo D., et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci U S A 2011, 108:20012-20017.
33. Daschkey S., Rottgers S., Giri A., et al. MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways. PLoS One 2013, 8:e56334.
34. Agata Y., Katakai T., Ye S.K., et al. Histone acetylation determines the developmentally regulated accessibility for T cell receptor gamma gene recombination. JExp Med 2001, 193:873-880.
35. Iwama A., Oguro H., Negishi M., et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004, 21:843-851.
36. Kamminga L.M., Bystrykh L.V., de Boer A., et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006, 107:2170-2179.
37. Rizo A., Olthof S., Han L., et al. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 2009, 114:1498-1505.
38. Ehrchen J.M., Sunderkotter C., Foell D., et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. JLeuk Biol 2009, 86:557-566.
39. He J., Xiao Z., Chen X., et al. The expression of functional Toll-like receptor 4 is associated with proliferation and maintenance of stem cell phenotype in endothelial progenitor cells (EPCs). JCell Biochem 2010, 111:179-186.
40. Baldridge M.T., King K.Y., Boles N.C., et al. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature 2010, 465:793-797.